The genomic landscape of breast cancer and its interaction with host immunity

被引：200

作者：

Luen, Stephen ^{[1
]}

Virassamy, Balaji ^{[1
]}

Savas, Peter ^{[1
]}

Salgado, Roberto ^{[2
]}

Loi, Sherene ^{[1
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Inst Jules Bordet, Brussels, Belgium

来源：

BREAST | 2016年 / 29卷

关键词：

Breast cancer; Immunity; Genomics; Immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; EXOME ANALYSIS REVEALS; MUTATIONAL PROCESSES; ANTICANCER CHEMOTHERAPY; RECEPTOR POLYMORPHISMS; PROGNOSTIC VALUE; PREDICTIVE-VALUE; DENDRITIC CELLS; T-CELLS; TRASTUZUMAB;

D O I：

10.1016/j.breast.2016.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular profiling of thousands of primary breast cancers has uncovered remarkable genomic diversity between breast cancer subtypes, and even within subtypes. Only a few driver genes are recurrently altered at high frequency highlighting great challenges for precision medicine. Considerable evidence also confirms the role, of host immunosurveillance in influencing response to therapy and prognosis in HER2+ and triple negative breast cancer. The role of immunosurveillance in ER + disease remains unclear. Advances in both these fields have lead to intensified interest in the interaction between genomic landscapes and host anti-tumour immune responses in breast cancer. In this review, we discuss the potential genomic determinants of host anti-tumour immunity - mutational load, driver alterations, mutational processes and neoantigens - and their relationship with immunity in breast cancer. Significant differences exist in both the genomic and immune characteristics amongst breast cancer subtypes. While ER + disease appears to be less immunogenic than HER2+ and triple negative breast cancer, it displays the greatest degree of heterogeneity. Mutational and neoantigen load appears to incompletely explains immune responses in breast cancer. Driver alterations do not appear to increase immunogenicity. Instead, they could contribute to immune-evasion or an immunosuppressive microenvironment, and therefore represent potential therapeutic targets. Finally, we also discuss the tailoring of immunotherapeutic strategies by genomic alterations, with possible multimodal combination approaches to maximise clinical benefits. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：241 / 250

页数：10

共 110 条

[51] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[52] Natural and therapy-induced immunosurveillance in breast cancer [J].

Kroemer, Guido ;

Senovilla, Laura ;

Galluzzi, Lorenzo ;

Andre, Fabrice ;

Zitvogel, Laurence .

NATURE MEDICINE, 2015, 21 (10) :1128-1138

[53] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [J].

Le, D. T. ;

Uram, J. N. ;

Wang, H. ;

Bartlett, B. R. ;

Kemberling, H. ;

Eyring, A. D. ;

Skora, A. D. ;

Luber, B. S. ;

Azad, N. S. ;

Laheru, D. ;

Biedrzycki, B. ;

Donehower, R. C. ;

Zaheer, A. ;

Fisher, G. A. ;

Crocenzi, T. S. ;

Lee, J. J. ;

Duffy, S. M. ;

Goldberg, R. M. ;

de la Chapelle, A. ;

Koshiji, M. ;

Bhaijee, F. ;

Huebner, T. ;

Hruban, R. H. ;

Wood, L. D. ;

Cuka, N. ;

Pardoll, D. M. ;

Papadopoulos, N. ;

Kinzler, K. W. ;

Zhou, S. ;

Cornish, T. C. ;

Taube, J. M. ;

Anders, R. A. ;

Eshleman, J. R. ;

Vogelstein, B. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2509-2520

[54] Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways [J].

Lim, Elgene ;

Wu, Di ;

Pal, Bhupinder ;

Bouras, Toula ;

Asselin-Labat, Marie-Liesse ;

Vaillant, Francois ;

Yagita, Hideo ;

Lindeman, Geoffrey J. ;

Smyth, Gordon K. ;

Visvader, Jane E. .

BREAST CANCER RESEARCH, 2010, 12 (02)

[55] Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial [J].

Loi, S. ;

Michiels, S. ;

Salgado, R. ;

Sirtaine, N. ;

Jose, V. ;

Fumagalli, D. ;

Kellokumpu-Lehtinen, P-L ;

Bono, P. ;

Kataja, V. ;

Desmedt, C. ;

Piccart, M. J. ;

Loibl, S. ;

Denkert, C. ;

Smyth, M. J. ;

Joensuu, H. ;

Sotiriou, C. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1544-1550

[56]

Loi S, 2016, CANC RES S, V76, P51

[57] RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors [J].

Loi, Sherene ;

Dushyanthen, Sathana ;

Beavis, Paul A. ;

Salgado, Roberto ;

Denkert, Carsten ;

Savas, Peter ;

Combs, Susan ;

Rimm, David L. ;

Giltnane, Jennifer M. ;

Estrada, Monica V. ;

Sanchez, Violeta ;

Sanders, Melinda E. ;

Cook, Rebecca S. ;

Pilkinton, Mark A. ;

Mallal, Simon A. ;

Wang, Kai ;

Miller, Vincent A. ;

Stephens, Phil J. ;

Yelensky, Roman ;

Doimi, Franco D. ;

Gomez, Henry ;

Ryzhov, Sergey V. ;

Darcy, Phillip K. ;

Arteaga, Carlos L. ;

Balko, Justin M. .

CLINICAL CANCER RESEARCH, 2016, 22 (06) :1499-1509

[58] Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 [J].

Loi, Sherene ;

Sirtaine, Nicolas ;

Piette, Fanny ;

Salgado, Roberto ;

Viale, Giuseppe ;

Van Eenoo, Francoise ;

Rouas, Ghizlane ;

Francis, Prudence ;

Crown, John P. A. ;

Hitre, Erika ;

de Azambuja, Evandro ;

Quinaux, Emmanuel ;

Di Leo, Angelo ;

Michiels, Stefan ;

Piccart, Martine J. ;

Sotiriou, Christos .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) :860-867

[59] Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells [J].

Ma, Yuting ;

Adjemian, Sandy ;

Mattarollo, Stephen R. ;

Yamazaki, Takahiro ;

Aymeric, Laetitia ;

Yang, Heng ;

Portela Catani, Joao Paulo ;

Hannani, Dalil ;

Duret, Helene ;

Steegh, Kim ;

Martins, Isabelle ;

Schlemmer, Frederic ;

Michaud, Mickael ;

Kepp, Oliver ;

Sukkurwala, Abdul Qader ;

Menger, Laurie ;

Vacchelli, Erika ;

Droin, Nathalie ;

Galluzzi, Lorenzo ;

Krzysiek, Roman ;

Gordon, Siamon ;

Taylor, Philip R. ;

Van Endert, Peter ;

Solary, Eric ;

Smyth, Mark J. ;

Zitvogel, Laurence ;

Kroemer, Guido .

IMMUNITY, 2013, 38 (04) :729-741

[60] PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer [J].

Majewski, Ian J. ;

Nuciforo, Paolo ;

Mittempergher, Lorenza ;

Bosma, Astrid J. ;

Eidtmann, Holger ;

Holmes, Eileen ;

Sotiriou, Christos ;

Fumagalli, Debora ;

Jimenez, Jose ;

Aura, Claudia ;

Prudkin, Ludmila ;

Carmen Diaz-Delgado, Maria ;

de la Pena, Lorena ;

Loi, Sherene ;

Ellis, Catherine ;

Schultz, Nikolaus ;

de Azambuja, Evandro ;

Harbeck, Nadia ;

Piccart-Gebhart, Martine ;

Bernards, Rene ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) :1334-1339

← 1 2 3 4 5 6 7 8 9 10 →